News

CRISPR/Cas9 Industry News

2021

2020

2019

2018

Statements and background on the CRISPR patent landscape

ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement
  ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models…
ERS Genomics and Nippon Gene sign CRISPR/Cas9 license agreement
License agreement to enhance Nippon Gene’s CRISPR/Cas9 research reagents offering Dublin, Ireland and Tokyo, Japan, 01 July 2021: ERS Genomics Limited, which was formed to…
ERS Genomics and genOway Enter CRISPR/Cas9 Agreement
Dublin, Ireland and Lyon, France, 07 June 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned…

Questions and answers about CRISPR patents

CVC’s issued patents are to the composition and use of the core type 2 CRISPR/Cas9 complex to modify DNA in ANY ENVIRONMENT without limitation to uses in eukaryotic cells. CVC further has issued patents on single guide RNA (sgRNA) which greatly enhances the efficiency of CRISPR gene editing in many applications.

In the United States, Broad’s issued patents (currently subject to a PTAB initiated interference) are for certain methods of genome editing and uses only in eukaryotic cells. 

In December, 2012, Broad requested “accelerated examination” of its application. This meant the USPTO considered the application more quickly. CVC did not request accelerated examination when it applied for a patent in May, 2012.

CRISPR research is a large field that involves contributions from many talented scientists around the world. The USPTO had issued more than 570 patents as of September 2020, with claims to CRISPR and/or Cas9 to approximately 900 inventors from more than 200 applicant organizations. The European Patent Office (EPO) had issued more than 190 such patents to more than 460 inventors from about 110 applicant institutions. In addition, there have been more than 9,200 applications filed (and published but not yet granted) around the world.

Current CVC patent list can be viewed here.

Over the next several years, there will be many more patents issued in the CRISPR field, to many inventors from many institutions, in recognition of each individual’s contribution to advancing CRISPR technology.

Latest news

ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement

  ERS Genomics and Japan SLC sign CRISPR/Cas9 license agreement Nobel prize winning CRISPR technology to be applied in development of genetically engineered animal models   DUBLIN, Ireland & Shizuoka, Japan, 27 July 2021: ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and Japan SLC, Inc., a biotechnology company providing animal models to the research community, today announced a non-exclusive license agreement granting Japan SLC access to ERS Genomics’ CRISPR/Cas9 patent portfolio. Japan SLC supports research organizations by providing animal models from its varied portfolio, including outbred,

Read more